Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 30.

Weiler, Stefan; Jetter, A (2017). Panzytopenie unter Methotrexat. Swiss Medical Forum, 17(28-29):594-596.

Weiler, S; Kullak-Ublick, G A; Jetter, A (2015). Klinisch relevante unerwünschte Arzneimittelinteraktionen: Tipps für die Praxis. Swiss Medical Forum, 15(7):152-156.

Weiler, S; Aellig, N; Fauchère, I; Jetter, A; Corti, N (2014). Treatment of gout in a renal transplant patient leading to severe thrombocytopenia. Journal of Clinical Pharmacy and Therapeutics, 39(5):571-572.

Ljung, R; Auerswald, G; Benson, G; Jetter, A; Jiménez-Yuste, V; Lambert, T; Morfini, M; Remor, E; Sørensen, B; Salek, S Z (2013). Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia, 19(4):481-486.

Taegtmeyer, A B; Kullak-Ublick, G A; Widmer, N; Falk, V; Jetter, A (2012). Clinical Usefulness of Electronic Drug-Drug Interaction Checking in the Care of Cardiovascular Surgery Inpatients. Cardiology, 123(4):219-222.

Bischoff-Ferrari, H A; Dawson-Hughes, B; Stöcklin, E; Sidelnikov, E; Willett, W C; Orav, E J; Stähelin, H B; Wolfram, S; Jetter, A; Schwager, J; Henschkowski, J; von Eckardstein, A; Egli, A (2012). Oral supplementation with 25(OH)D(3) versus vitamin D(3) : effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity. Journal of Bone and Mineral Research, 27(1):160-169.

Taegtmeyer, A B; Ceschi, A; Kullak-Ublick, G A; Jetter, A (2012). Pharmakogenetik in der Praxis: warum, wie, wann? - Teil 1. Swiss Medical Forum, 12(42):808-811.

Taegtmeyer, A B; Ceschi, A; Kullak-Ublick, G A; Jetter, A (2012). Pharmakogenetik in der Praxis: warum, wie, wann? - Teil 2. Swiss Medical Forum, 12(42):824-826.

Jetter, A. Beeinflussung und Quantifizierung der Aktivitäten arzneistoffmetabolisierender Enzyme bei Gesunden und Kranken. 2011, University of Zurich, Faculty of Medicine.

Wyen, C; Hendra, H; Siccardi, M; Platten, M; Jaeger, H; Harrer, T; Esser, S; Bogner, J R; Brockmeyer, N H; Bieniek, B; Rockstroh, J; Hoffmann, C; Stoehr, A; Michalik, C; Dlugay, V; Jetter, A; Knechten, H; Klinker, H; Skaletz-Rorowski, A; Fätkenheuer, G; Egan, D; Back, D J; Owen, A (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Journal of Antimicrobial Chemotherapy, 66(9):2092-2098.

Tomalik-Scharte, D; Fuhr, U; Hellmich, M; Frank, D; Doroshyenko, O; Jetter, A; Stingl, J C (2011). Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metabolism and Disposition, 39(5):927-932.

Toniolo, M; Jetter, A (2011). Methotrexat und Cotrimoxazol bei rheumatologischen Patienten. Rheuma Schweiz, 3(5):47-49.

Opitz, I; Erne, B V; Demirbas, S; Jetter, A; Seifert, Burkhardt; Stahel, R; Weder, W (2011). Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study. Journal of Thoracic and Cardiovascular Surgery, 141(1):65-71.

Ceschi, A; Curkovic, I; Kirchheiner, J; Kullak-Ublick, G; Jetter, A (2010). Arzneimittelinteraktionen mit antiretroviralen Medikamenten. Der Internist, 51(1):94-99.

Abduljalil, K; Frank, D; Gaedigk, A; Klaassen, T; Tomalik-Scharte, D; Jetter, A; Jaehde, U; Kirchheiner, J; Fuhr, U (2010). Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clinical Pharmacology and Therapeutics, 88(5):643-651.

Jetter, A; Fätkenheuer, G; Frank, D; Klaassen, T; Seeringer, A; Doroshyenko, O; Kirchheiner, J; Hein, W; Schömig, E; Fuhr, U; Wyen, C (2010). Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antiviral Therapy, 15(7):975-983.

Non adherence - non response. Edited by: Kullak-Ublick, G A; Jetter, A (2010). Bern, CH: Hans Huber Verlag.

Jetter, A; Kullak-Ublick, G A (2010). Non adherence – non response. Therapeutische Umschau, 67(6):281-282.

Russmann, S; Jetter, A; Kullak-Ublick, G A (2010). Pharmacogenetics of drug-induced liver injury. Hepatology, 52(2):748-761.

Tomalik-Scharte, D; Lütjohann, D; Doroshyenko, O; Frank, D; Jetter, A; Fuhr, U (2009). Plasma 4beta-Hydroxycholesterol: An Endogenous CYP3A Metric? Clinical Pharmacology and Therapeutics, 86(2):147-153.

Jetter, A; Kinzig, M; Rodamer, M; Tomalik-Scharte, D; Sörgel, F; Fuhr, U (2009). Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? European Journal of Clinical Pharmacology, 65(4):411-417.

Lück, H; Kinzig, M; Jetter, A; Fuhr, U; Sörgel, F (2009). Mesalazine pharmacokinetics and NAT2 phenotype. European Journal of Clinical Pharmacology, 64(1):47-54.

Corti, N; Heck, A; Rentsch, K; Zingg, W; Jetter, A; Stieger, B; Pauli-Magnus, C (2009). Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. European Journal of Clinical Pharmacology, 65(10):999-1006.

Doroshyenko, O; Fuhr, U; Kunz, D; Frank, D; Kinzig, M; Jetter, A; Reith, Y; Lazar, A; Taubert, D; Kirchheiner, J; Baum, M; Eisenbrand, G; Berger, F I; Bertow, D; Berkessel, A; Sörgel, F; Schömig, E; Tomalik-Scharte, D (2009). In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans. Cancer Epidemiology Biomarkers & Prevention, 18(2):433-443.

Muschler, E; Lal, J; Jetter, A; Rattay, A; Zanger, U; Zadoyan, G; Fuhr, U; Kirchheiner, J (2009). The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic & Clinical Pharmacology & Toxicology, 105(6):374-379.

Tomalik-Scharte, D; Doroshyenko, O; Kirchheiner, J; Jetter, A; Lazar, A; Klaassen, T; Frank, D; Wyen, C; Fätkenheuer, G; Fuhr, U (2008). No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. European Journal of Clinical Pharmacology, 64(10):1033-1035.

Lazar, A; Jetter, A (2008). Pharmakogenetik in der Onkologie: 5-Fluorouracil und die Dihydropyrimidin-Dehydrogenase. Deutsche Medizinische Wochenschrift, 133(28-29):1501-1504.

Klaassen, T; Jetter, A; Tomalik-Scharte, D; Kasel, D; Kirchheiner, J; Jaehde, U; Fuhr, U (2008). Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. European Journal of Clinical Pharmacology, 64(4):387-398.

Wyen, C; Fuhr, U; Frank, D; Aarnoutse, R E; Klaassen, T; Lazar, A; Seeringer, A; Doroshyenko, O; Kirchheiner, J C; Abdulrazik, F; Schmeisser, N; Lehmann, C; Hein, W; Schömig, E; Burger, D M; Fätkenheuer, G; Jetter, A (2008). Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clinical Pharmacology and Therapeutics, 84(1):75-82.

Wyen, C; Hendra, H; Vogel, M; Hoffmann, C; Knechten, H; Brockmeyer, N H; Bogner, J R; Rockstroh, J; Esser, S; Jaeger, H; Harrer, T; Mauss, S; van Lunzen, J; Skoetz, N; Jetter, A; Groneuer, C; Fätkenheuer, G; Khoo, S H; Egan, D; Back, D J; Owen, A (2008). Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 61(4):914-918.

This list was generated on Mon Jun 17 05:14:14 2019 CEST.